Trial Profile
A phase II trial of enfortumab vedotin in patients with urothelial cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2021
Price :
$35
*
At a glance
- Drugs Enfortumab vedotin (Primary)
- Indications Urogenital cancer
- Focus Registrational; Therapeutic Use
- Sponsors Seagen
- 01 Aug 2017 Planned number of patients changed to 120.
- 14 Feb 2017 New trial record